Seth Klarman’s Bristol-Myers Squibb BMY Stock Holding History

Seth Klarman’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,000,000	Closed	-$257M	–	34
2019 Q4	$257M	Sell	4,000,000 -6,000,000	-60%	-$344M	2.84%	9
2019 Q3	$507M	Sell	10,000,000 -3,000,000	-23%	-$141M	5.74%	6
2019 Q2	$590M	Buy	13,000,000 +9,000,000	+225%	+$419M	5.34%	7
2019 Q1	$191M	Buy	+4,000,000	New	+$199M	1.6%	24

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Seth Klarman's BMY Position: Q1 2020 in Review

Seth Klarman sold out of Bristol-Myers Squibb (BMY) in Q1 2020, closing a stake of 4,000,000 shares — an estimated $257M sold.

Seth Klarman first reported a position in BMY in Q1 2019 and held it in 4 quarters. The position peaked at $590M in Q2 2019. 2,149 funds tracked by Wall St. Rank hold BMY as of Q1 2020.

Seth Klarman reported no remaining Bristol-Myers Squibb position as of Q1 2020 after selling out during the quarter.
Seth Klarman sold 4,000,000 Bristol-Myers Squibb shares in Q1 2020, an estimated $257M.
Seth Klarman first reported a position in Bristol-Myers Squibb in Q1 2019 and held it in 4 quarters.
Seth Klarman's Bristol-Myers Squibb position peaked at $590M in Q2 2019.
2,149 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2020.

Based on Baupost Group's 13F filing for Q1 2020, filed 14 May 2020.